BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane.
The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics.
A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients.
The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation.
BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services.
While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
As Google AI Takes Over Search, News Sites Lose Clicks and Cut Jobs
Google (NASDAQ:GOOG) is drawing criticism from media executives who say its growing use of artificial intelligence is reducing traffic to news outlets, forcing them to rethink their digital strategies and slash jobs. According to a Wall Street Journal report Tuesday, publishers are reporting major declines in referral traffic as Google's AI Overviews and chatbot features increasingly serve answers directly to users eliminating the need to click on search results. The shift from a search engine to an answer engine is real, said The Atlantic's CEO Nicholas Thompson, who added that media companies now have to explore new approaches to stay relevant. Data from analytics firm Similarweb, cited in the report, shows steep drops in organic search traffic across major publishers: HuffPost's desktop and mobile traffic more than halved in the past three years. The Washington Post saw nearly the same level of decline. Business Insider reported a 55% drop and recently laid off 21% of its workforce. The New York Times saw its share of organic search traffic shrink to 36.5% in April 2025, down from almost 44% in 2022. Although The Wall Street Journal's search traffic rose in raw numbers, its share of total traffic dipped to 24% from 29% over the same period. WaPo CEO William Lewis warned that click-free search answers represent a serious threat to journalism. Beyond news, Google's AI tools have also dented traffic to travel guides, health information, and product review pages. The report notes that Google's upcoming AI Mode could hit even harder. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Here's Why LifeVantage (NASDAQ:LFVN) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. In contrast to all that, many investors prefer to focus on companies like LifeVantage (NASDAQ:LFVN), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Even modest earnings per share growth (EPS) can create meaningful value, when it is sustained reliably from year to year. So it's easy to see why many investors focus in on EPS growth. Impressively, LifeVantage's EPS catapulted from US$0.29 to US$0.73, over the last year. It's not often a company can achieve year-on-year growth of 154%. One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The good news is that LifeVantage is growing revenues, and EBIT margins improved by 4.1 percentage points to 5.8%, over the last year. Both of which are great metrics to check off for potential growth. You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image. See our latest analysis for LifeVantage In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of LifeVantage's forecast profits? It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own LifeVantage shares worth a considerable sum. To be specific, they have US$30m worth of shares. This considerable investment should help drive long-term value in the business. That amounts to 19% of the company, demonstrating a degree of high-level alignment with shareholders. LifeVantage's earnings have taken off in quite an impressive fashion. That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering LifeVantage for a spot on your watchlist. Of course, just because LifeVantage is growing does not mean it is undervalued. If you're wondering about the valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. Although LifeVantage certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
35 minutes ago
- Yahoo
Cardano's ADA Gains 3%, Buoyed by Inclusion in Nasdaq's Crypto Index
Cardano's native token ADA ADA added 3% in the past 24 hours after Nasdaq said it expanded its crypto benchmark index from five to nine assets, adding ADA alongside XRP XRP, Solana SOL and Stellar XLM. ADA experienced significant price volatility overnight, establishing a 8.8% trading range between $0.66 and $0.72, according to CoinDesk Research's technical analysis. It was recently trading at $0.6951. Trading volumes for ADA have increased 68% over the past 24 hours, suggesting active market participation despite uncertain conditions. Its addition to the Nasdaq index could significantly increase Cardano's visibility among traditional investors. Market analysts note the $0.70 level has emerged as a crucial psychological support zone that will likely determine ADA's short-term trajectory following its earlier bullish momentum. The CoinDesk 20 Index, which tracks the broader crypto market performance, is up about 4% over the past 24 hours. Technical Analysis ADA exhibited significant volatility over the 24-hour period, establishing a 8.8% trading range between $0.66 and $0.72 before dropping 3.3%. The price action formed a clear uptrend from $0.67 to $0.72 with strong volume support at the $0.68 level. The recent pullback from $0.72 to $0.69 suggests profit-taking after the rally, with the 0.70 level emerging as a key psychological support zone. Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
